Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Telix Pharmaceuticals Limited

TLPPFPNK
Healthcare
Biotechnology
$6.77
$-0.18(-2.59%)
U.S. Market opens in 9h 43m

Telix Pharmaceuticals Limited Fundamental Analysis

Telix Pharmaceuticals Limited (TLPPF) shows moderate financial fundamentals with a PE ratio of -297.87, profit margin of -0.89%, and ROE of -2.08%. The company generates $1.2B in annual revenue with strong year-over-year growth of 55.85%.

Key Strengths

No significant strengths identified.

Areas of Concern

ROE-2.08%
Operating Margin2.11%
We analyze TLPPF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 31.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
31.4/100

We analyze TLPPF's fundamental strength across five key dimensions:

Efficiency Score

Weak

TLPPF struggles to generate sufficient returns from assets.

ROA > 10%
-0.61%

Valuation Score

Excellent

TLPPF trades at attractive valuation levels.

PE < 25
-297.87
PEG Ratio < 2
1.64

Growth Score

Moderate

TLPPF shows steady but slowing expansion.

Revenue Growth > 5%
55.85%
EPS Growth > 10%
8.20%

Financial Health Score

Moderate

TLPPF shows balanced financial health with some risks.

Debt/Equity < 1
1.26
Current Ratio > 1
1.43

Profitability Score

Weak

TLPPF struggles to sustain strong margins.

ROE > 15%
-207.84%
Net Margin ≥ 15%
-0.89%
Positive Free Cash Flow
No

Key Financial Metrics

Is TLPPF Expensive or Cheap?

P/E Ratio

TLPPF trades at -297.87 times earnings. This suggests potential undervaluation.

-297.87

PEG Ratio

When adjusting for growth, TLPPF's PEG of 1.64 indicates fair valuation.

1.64

Price to Book

The market values Telix Pharmaceuticals Limited at 5.19 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.19

EV/EBITDA

Enterprise value stands at 71.77 times EBITDA. This signals the market has high growth expectations.

71.77

How Well Does TLPPF Make Money?

Net Profit Margin

For every $100 in sales, Telix Pharmaceuticals Limited keeps $-0.89 as profit after all expenses.

-0.89%

Operating Margin

Core operations generate 2.11 in profit for every $100 in revenue, before interest and taxes.

2.11%

ROE

Management delivers $-2.08 in profit for every $100 of shareholder equity.

-2.08%

ROA

Telix Pharmaceuticals Limited generates $-0.61 in profit for every $100 in assets, demonstrating efficient asset deployment.

-0.61%

Following the Money - Real Cash Generation

Operating Cash Flow

Telix Pharmaceuticals Limited generates limited operating cash flow of $-27.38M, signaling weaker underlying cash strength.

$-27.38M

Free Cash Flow

Telix Pharmaceuticals Limited generates weak or negative free cash flow of $-77.63M, restricting financial flexibility.

$-77.63M

FCF Per Share

Each share generates $-0.23 in free cash annually.

$-0.23

FCF Yield

TLPPF converts -2.40% of its market value into free cash.

-2.40%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-297.87

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.64

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.19

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.64

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.26

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.43

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.02

vs 25 benchmark

ROA

Return on assets percentage

-0.01

vs 25 benchmark

ROCE

Return on capital employed

0.02

vs 25 benchmark

How TLPPF Stacks Against Its Sector Peers

MetricTLPPF ValueSector AveragePerformance
P/E Ratio-297.8729.45 Better (Cheaper)
ROE-2.08%779.00% Weak
Net Margin-0.89%-24936.00% (disorted) Weak
Debt/Equity1.260.26 Weak (High Leverage)
Current Ratio1.434.65 Neutral
ROA-0.61%-19344.00% (disorted) Weak

TLPPF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Telix Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

15738.68%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

226.25%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

229.97%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ